Ascendiant Capital Markets Issues Pessimistic Forecast for NovaBay Pharmaceuticals (NYSE:NBY) Stock Price

NovaBay Pharmaceuticals (NYSE:NBY) had its price objective cut by Ascendiant Capital Markets from $8.00 to $0.85 in a research note published on Monday,Benzinga reports. They currently have a buy rating on the stock.

Separately, StockNews.com began coverage on shares of NovaBay Pharmaceuticals in a research report on Saturday, November 9th. They issued a “hold” rating on the stock.

NovaBay Pharmaceuticals Trading Down 8.7 %

NBY opened at $0.71 on Monday. The stock has a market capitalization of $3.48 million, a P/E ratio of -0.01 and a beta of 0.73. NovaBay Pharmaceuticals has a 12 month low of $0.36 and a 12 month high of $12.08. The firm’s fifty day simple moving average is $0.63 and its 200 day simple moving average is $1.63.

NovaBay Pharmaceuticals (NYSE:NBY) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($1.37) EPS for the quarter. The company had revenue of $2.40 million during the quarter. NovaBay Pharmaceuticals had a negative net margin of 102.72% and a negative return on equity of 7,293.78%. On average, equities research analysts predict that NovaBay Pharmaceuticals will post -1.41 EPS for the current fiscal year.

NovaBay Pharmaceuticals Company Profile

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.